» Articles » PMID: 22741032

Beyond Antiangiogenesis: Vascular Modulation As an Anticancer Therapy-a Review

Overview
Journal Transl Oncol
Specialty Oncology
Date 2012 Jun 29
PMID 22741032
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This review attempts to move beyond the traditional borders of antiangiogenesis and toward the dynamic, evolving strategies of vascular modulation. This repositioning entails a two-fold paradigm shift: conceptually, to a view of antiangiogenesis as only one part of a larger story, and therapeutically, to approaches which attempt to modulate tumor blood flow instead of simply inhibiting it. Three vascular modulation strategies-provascular, antivascular, and redistributive-are presented with representative compounds. These vascular modulation strategies are described in specific measurable characteristics (blood vessel maturity and type, effect on blood flow, microenvironmental target, molecular target, angiogenic biomarker, and imaging biomarkers) that will help define the tumor types that are more susceptible to a particular vascular modulation strategy thereby guiding therapeutic agent selection and enabling a personalized medicine approach.

Citing Articles

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.

Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T Front Oncol. 2023; 13:1204143.

PMID: 37313460 PMC: 10258348. DOI: 10.3389/fonc.2023.1204143.


Gene Therapy of Chronic Limb-Threatening Ischemia: Vascular Medical Perspectives.

Simon F, Duran M, Garabet W, Schelzig H, Jacobs M, Gombert A J Clin Med. 2022; 11(5).

PMID: 35268373 PMC: 8910863. DOI: 10.3390/jcm11051282.


A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?.

Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M Med Oncol. 2016; 33(7):63.

PMID: 27229330 DOI: 10.1007/s12032-016-0775-3.


RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Oronsky B, Scicinski J, Cabrales P, Minchinton A Clin Epigenetics. 2016; 8:53.

PMID: 27175220 PMC: 4864927. DOI: 10.1186/s13148-016-0220-7.


Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter C, Degesys A, Oronsky B, Scicinski J, Caroen S, Oronsky A Case Rep Oncol. 2015; 8(3):461-5.

PMID: 26600780 PMC: 4649750. DOI: 10.1159/000441775.


References
1.
Schlingemann R, Rietveld F, Kwaspen F, van de Kerkhof P, de Waal R, Ruiter D . Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol. 1991; 138(6):1335-47. PMC: 1886404. View

2.
Greenberg J, Shields D, Barillas S, Acevedo L, Murphy E, Huang J . A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008; 456(7223):809-13. PMC: 2605188. DOI: 10.1038/nature07424. View

3.
Hama Y, Suzuki K, Shingu K, Fujimori M, Kobayashi S, Usuda N . Three-dimensional structure of the micro-blood vessels in thyroid tumors analyzed by immunohistochemistry coupled with image analysis. Thyroid. 1999; 9(9):927-32. DOI: 10.1089/thy.1999.9.927. View

4.
Jain R, Booth M . What brings pericytes to tumor vessels?. J Clin Invest. 2003; 112(8):1134-6. PMC: 213497. DOI: 10.1172/JCI20087. View

5.
Papetti M, Herman I . Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002; 282(5):C947-70. DOI: 10.1152/ajpcell.00389.2001. View